X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (121) 121
humans (114) 114
index medicus (94) 94
female (86) 86
male (82) 82
middle aged (79) 79
aged (74) 74
lung neoplasms - drug therapy (64) 64
adult (62) 62
lung cancer (55) 55
chemotherapy (53) 53
lung neoplasms - genetics (52) 52
lung neoplasms - pathology (52) 52
carcinoma, non-small-cell lung - drug therapy (50) 50
mutation (36) 36
lung cancer, non-small cell (34) 34
aged, 80 and over (31) 31
cancer (31) 31
respiratory system (31) 31
carcinoma, non-small-cell lung - genetics (29) 29
gefitinib (28) 28
treatment outcome (28) 28
non-small cell lung cancer (26) 26
disease-free survival (23) 23
neoplasm staging (23) 23
protein kinase inhibitors - therapeutic use (23) 23
antineoplastic agents - therapeutic use (22) 22
carcinoma, non-small-cell lung - pathology (22) 22
patients (22) 22
adenocarcinoma (21) 21
open-label (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
hematology, oncology and palliative medicine (19) 19
receptor, epidermal growth factor - genetics (19) 19
survival (19) 19
epidermal growth factor (18) 18
erlotinib (18) 18
metastasis (17) 17
retrospective studies (17) 17
tumors (17) 17
care and treatment (16) 16
expression (16) 16
japan (16) 16
non-small-cell lung cancer (16) 16
quinazolines - therapeutic use (16) 16
adenocarcinoma - genetics (15) 15
analysis (15) 15
lung neoplasms - metabolism (15) 15
nivolumab (15) 15
docetaxel (14) 14
lung neoplasms - mortality (14) 14
resistance (14) 14
safety (14) 14
survival analysis (14) 14
therapy (14) 14
trial (14) 14
cell line, tumor (13) 13
clinical trials (13) 13
lung neoplasms - enzymology (13) 13
antineoplastic agents - adverse effects (12) 12
cancer therapies (12) 12
cisplatin (12) 12
crizotinib (12) 12
epidermal growth factor receptor (12) 12
gene (12) 12
research (12) 12
tyrosine (12) 12
adenocarcinoma - drug therapy (11) 11
adenocarcinoma - pathology (11) 11
cell lung-cancer (11) 11
medical research (11) 11
mutations (11) 11
1st-line treatment (10) 10
animals (10) 10
asian continental ancestry group (10) 10
carcinoma, small cell - genetics (10) 10
cisplatin - administration & dosage (10) 10
epidermal growth factor receptors (10) 10
medicine, experimental (10) 10
mice (10) 10
nsclc (10) 10
oncology, experimental (10) 10
original (10) 10
prognosis (10) 10
protein-tyrosine kinase (10) 10
pulmonary/respiratory (10) 10
survival rate (10) 10
tyrosine kinase inhibitor (10) 10
carcinoma, non-small-cell lung - mortality (9) 9
egfr mutation (9) 9
erbb receptors - genetics (9) 9
genetic aspects (9) 9
inhibitor (9) 9
lung cancer, small cell (9) 9
multicenter (9) 9
non-small cell lung carcinoma (9) 9
pharmaceuticals (9) 9
receptor protein-tyrosine kinases - genetics (9) 9
surgery (9) 9
tumor cells, cultured (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10066, pp. 255 - 265
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 09/2015, Volume 106, Issue 9, pp. 1202 - 1211
In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma... 
Afatinib | chemotherapy | Japanese | epidermal growth factor receptor | non‐small cell lung cancer | Chemotherapy | Epidermal growth factor receptor | Non-small cell lung cancer | non-small cell lung cancer | CARBOPLATIN-PACLITAXEL | SURVIVAL | 1ST-LINE TREATMENT | TYROSINE KINASE DOMAIN | ADENOCARCINOMA | OPEN-LABEL | GEFITINIB TREATMENT | GROWTH-FACTOR RECEPTOR | RANDOMIZED PHASE-3 TRIAL | ONCOLOGY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Adenocarcinoma of Lung | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Asian Continental Ancestry Group - genetics | ErbB Receptors - genetics | Male | Mutation - genetics | Adenocarcinoma - drug therapy | Cisplatin - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Pemetrexed - administration & dosage | Adult | Female | Adenocarcinoma - genetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma | Appetite | Leukopenia | Epidermal growth factor receptors | Research funding | Acne | Lung cancer | Diarrhea | Nausea | Cancer therapies | Patients | Disease control | Cisplatin | Confidence intervals | Studies | Stomatitis | Epidermal growth factor | Mutation | Drug dosages | Neutropenia | Pharmaceuticals | Tumors | Original
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Journal Article
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Introduction Development of cancer treatment such as targeted drugs and anti-PD-1 inhibitors resulted in the prolongation of survival time in advanced... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, p. vi91
Journal Article